Navigation Links
VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease
Date:6/11/2009

of words such as "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue" or the negative of these terms or other comparable terminology. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond VIA's control and which could materially affect actual results, levels of activity, performance or achievements.

Factors that may cause actual results to differ materially from current expectations include, but are not limited to:

    -- our ability to borrow additional amounts under the loan from Bay City
       Capital, which is subject to the discretion of Bay City Capital;
    -- our ability to obtain necessary financing in the near term, including
       amounts necessary to repay the loan from Bay City Capital by the
       September 14, 2009 maturity date (or earlier if certain repayment
       acceleration provisions are triggered);
    -- our ability to control our operating expenses;
    -- our ability to comply with covenants included in the loan from Bay
       City Capital;
    -- our ability to maintain the listing of our common stock on NASDAQ;
    -- our failure to timely recruit and enroll patients for the FDG-PET
       clinical trial, as well as any future clinical trial;
     -- our failure to obtain sufficient data from enrolled patients that can
       be used to evaluate VIA- 2291, thereby impairing the validity or
       statistical significance of our clinical trials;
    -- our ability to successfully complete our clinical trials of VIA-2291
       on expected timetables and the outcomes of such clinical trials;
    -- complexities in designing and implementing cardiovascular clinical
       trials using histological examinations, measurement of biomarkers,
       medical imaging and atherosclerotic plaque bioassays;

'/>"/>
SOURCE VIA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Oramed Pharmaceuticals to Present at the 8th National Life Science & Technology Week ILSI -BIOMED Conference, Israel 2009
2. Merz Pharmaceuticals Announce Three Studies of NT-201 - (Botulinum neurotoxin type A Free From Complexing Proteins)
3. ISTA Pharmaceuticals Announces Positive Results for Phase 2 Study of Low-Dose Bromfenac in Dry Eye Disease
4. Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting
5. Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk
6. Access Pharmaceuticals Announces Publication of Thiarabine Combination Data
7. Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials
8. Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Associations 69th Scientific Sessions
9. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
10. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... Israel , June 29, 2015 ... today announced positive preliminary results from its BVX-006 Phase ... universal influenza vaccine. In this trial, M-001 was injected ... 65, followed by an administration of the 2014/15 season ... found to be safe and well tolerated and induced ...
(Date:6/29/2015)... , June 29, 2015 DURECT Corporation ... James E. Brown , President and CEO, will ... on Wednesday, July 8 at 11:45 a.m. Eastern ... Parker Meridien Hotel in New York City.  Investors ... request a one-on-one meeting through the conference organizers ...
(Date:6/29/2015)... 29, 2015 Axxess , an industry ... only software vendor accredited by the American Nursing Credentialing ... home health agencies select the right revenue cycle management ... grow their business. Research by American Health ... should expect a decrease in productivity of 54.4 - ...
Breaking Medicine Technology:BiondVax Presents BVX-006 Preliminary Phase II Results: the Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults 2BiondVax Presents BVX-006 Preliminary Phase II Results: the Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults 3DURECT to Present at the Cantor Fitzgerald Healthcare Conference 2Axxess Releases eGuide for Home Health Agencies, Revenue Cycle Management: What You Must Do Now - to Succeed! 2
... CSA Medical, Inc. announced today that New ... providing Spray Cryotherapy treatment for patients. Dr. Costas ... department of Cardiothoracic Surgery is performing this procedure. ... in the Department of Cardiothoracic Surgery at NYU ...
... 20 Despite Tylenol,s product recalls and plant closure, ... consumers, according to a research study released today. ... and build loyalty to them in the same way ... terms of warmth and competence – and these judgments ...
Cached Medicine Technology:CSA Medical, Inc. Announces 75th Customer 2Study of Brands Shows Tylenol Maintains Consumer Loyalty Despite Recent Quality Challenges 2
(Date:6/29/2015)... ... June 29, 2015 , ... National ... auditor of customer service for the 40-center nursing home group. Sixteen of their ... centers in the United States in one or more customer service areas. Those ...
(Date:6/29/2015)... Newark, Delaware (PRWEB) , ... June 29, 2015 , ... ... Exam Master® announces a partnership with the American Board of Urgent Care Medicine and ... AMA PRA Category 1 Credit™ to Urgent Care physicians and health care professionals. , ...
(Date:6/29/2015)... ... June 29, 2015 , ... OR Manager announced Monday the ... and feel, as well as a redesigned logo and weekly eLetter. The website contains ... now more user-friendly and easier to navigate. , In addition to a refreshed ...
(Date:6/29/2015)... ... June 29, 2015 , ... The Food Safety and ... The Hong Kong Polytechnic University (PolyU) has developed a new method for rapid ... has been a long-term issue in food safety, and becomes particularly important with ...
(Date:6/29/2015)... (PRWEB) , ... June 29, 2015 , ... ... between personality type and behavior, is a popular focus for corporate training seminars. ... to streamline hiring practices, improve training, foster teamwork, and increase productivity. , ...
Breaking Medicine News(10 mins):Health News:National HealthCare Centers Receive 'Customer Experience Awards' 2Health News:National HealthCare Centers Receive 'Customer Experience Awards' 3Health News:National HealthCare Centers Receive 'Customer Experience Awards' 4Health News:Exam Master Partners to Provide New Urgent Care Continuing Medical Education Resource 2Health News:Exam Master Partners to Provide New Urgent Care Continuing Medical Education Resource 3Health News:OR Manager Launches New Website 2Health News:PolyU develops a new method for rapid authentication of edible oils and screening of gutter oils 2Health News:As Demand for DISC Trainers Rises, PeopleKeys Offers Support with “THE DISC FACTOR—Train the Trainer” Webinar 2
... to Digital Converters, with Integrated Signal Compression, Received ... 2008; Samplify,s Prism(TM) Lossless Data Compression Technology Named ... Jan 21 Samplify Systems, Inc., a provider ... is pleased to announce it has received top ...
... Global Marketing Will Oversee Life Sciences Software Group , ... ... Group LTD ("KineMatik"), providers of software solutions for managing scientific ... Michael G. Jarjour as President & CEO., , ,Mr. Jarjour, ...
... one of the industry,s most respected suppliers of adult diapers, walkers, ... a name for itself online as the leader in Customer Service ... ... Greenville, SC (PRWEB) January 21, 2009 -- Homecare is the fastest ...
... Children,s Health Journal has just come out. In it,s 23rd year it ... and developmental progress. It is both a keepsake, and a lifesaver in ... since its inception. A diaper bag must. , ... Fountain Valley, CA ...
... 20 Nationwide Health Properties, Inc. (NYSE: NHP ) announced the tax treatment for its ... 2008:, COMMON STOCK (CUSIP# 638620104), 2008 ... Taxable Return Total Unrecaptured, Record ... Capital Section, Date ...
... South Africa,s new Children,s Act came into effect, granting ... relating to reproductive health, including the right to access ... decide whether or not to give out condomspolicies that ... , say could damage the health of the country,s ...
Cached Medicine News:Health News:Samplify Systems Receives Top Honors From Electronic Products and EDN Magazines 2Health News:Samplify Systems Receives Top Honors From Electronic Products and EDN Magazines 3Health News:KineMatik Group Ltd. Appoints Michael G. Jarjour as President & CEO 2Health News:KineMatik Group Ltd. Appoints Michael G. Jarjour as President & CEO 3Health News:Home Delivery Medical Transforms Customer Service On the Web for Seniors and Homecare Providers 2Health News:Home Delivery Medical Transforms Customer Service On the Web for Seniors and Homecare Providers 3Health News:Pocket Reference Journals Releases Latest Edition of "All About Me" Leading Children's Immunization Journal for New Moms 2Health News:Pocket Reference Journals Releases Latest Edition of "All About Me" Leading Children's Immunization Journal for New Moms 3Health News:NHP Announces Tax Treatment of 2008 Distributions 2Health News:NHP Announces Tax Treatment of 2008 Distributions 3Health News:South African policy on adolescents' rights to access condoms is causing confusion 2
... patented telescoping plate design integrates ... plate and vertebral column spacer. ... the need for supplemental fixation ... of bone graft to be ...
... is a resorbable, osteoconductive matrix consisting of ... use in oral maxillofacial procedures as a ... Osteon 200R has been FDA indicated as ... is replaced with bone during the healing ...
O-arm combines the best features of a traditional c-arm with an intra-operative 3D scannerfor unparalleled surgical imaging....
A patient care system tailored to your specific needs that supports current and previous-generation ICDs and pacemakers....
Medicine Products: